NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $23.85 -1.19 (-4.75%) Closing price 04:00 PM EasternExtended Trading$23.85 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zenas BioPharma Stock (NASDAQ:ZBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$23.78▼$25.6450-Day Range$24.84▼$33.0552-Week Range$13.50▼$44.60Volume576,516 shsAverage Volume773,572 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$46.71Consensus RatingModerate Buy Company Overview Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.AI Generated. May Contain Errors. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreZBIO MarketRank™: 3.17148335844 of 5 starsZenas BioPharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 236th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingZenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialZenas BioPharma has a consensus price target of $46.71, representing about 87.7% upside from its current price of $24.89.Amount of Analyst CoverageZenas BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zenas BioPharma are expected to grow in the coming year, from ($6.23) to ($4.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 7.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.33% of the float of Zenas BioPharma has been sold short.Short Interest Ratio / Days to CoverZenas BioPharma has a short interest ratio ("days to cover") of 24.08, which indicates bearish sentiment.Change versus previous monthShort interest in Zenas BioPharma has recently decreased by 9.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.60 News SentimentZenas BioPharma has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zenas BioPharma this week, compared to 4 articles on an average week.Search Interest2 people have searched for ZBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsZenas BioPharma has minimal institutional ownership at this time.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZBIO Stock News HeadlinesZenas BioPharma Announces Inducement Grants to Newly Hired EmployeesNovember 18 at 4:31 PM | quiverquant.comQZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 18 at 4:15 PM | globenewswire.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.November 20 at 1:00 AM | Banyan Hill Publishing (Ad)Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related DiseaseNovember 17 at 7:00 AM | globenewswire.comFY2026 EPS Forecast for Zenas BioPharma Decreased by AnalystNovember 13, 2026 | americanbankingnews.comZenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on WednesdayNovember 11, 2026 | americanbankingnews.comZenas BioPharma to Present at the Jefferies London Global Healthcare ConferenceNovember 9, 2026 | finance.yahoo.comZenas BioPharma Launches New $200 Million Stock OfferingNovember 6, 2026 | tipranks.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $36.31 at the start of the year. Since then, ZBIO stock has decreased by 31.5% and is now trading at $24.8890. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) released its quarterly earnings results on Thursday, November, 5th. The company reported ($1.65) EPS for the quarter, missing analysts' consensus estimates of ($1.24) by $0.41. The firm had revenue of $10 million for the quarter, compared to analyst estimates of $10 million. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an initial public offering on Thursday, September 12th 2024. The company issued 13,235,294 shares at $16.00-$18.00 per share. Who are Zenas BioPharma's major shareholders? Top institutional investors of Zenas BioPharma include State Street Corp (2.78%), Goldman Sachs Group Inc. (1.14%), Candriam S.C.A. (1.00%) and Marshall Wace LLP (0.25%). Insiders that own company stock include Fairmount Funds Management Llc, Sr One Capital Management, Llc, Jason Raleigh Nunn, Hongbo Lu, Leon O Moulder Jr, Patricia L Allen and Patrick G Enright. View institutional ownership trends. How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/05/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ZBIO's financial health is in the Green zone, according to TradeSmith. ZBIO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 Webzenasbio.com Phone(857) 271-2954FaxN/AEmployees167Year Founded2019Price Target and Rating Average Price Target for Zenas BioPharma$46.71 High Price Target$55.00 Low Price Target$32.00 Potential Upside/Downside+95.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($9.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$377.74 million Net MarginsN/A Pretax Margin-4,923.08% Return on Equity-144.65% Return on Assets-59.83% Debt Debt-to-Equity Ratio1.88 Current Ratio9.42 Quick Ratio9.42 Sales & Book Value Annual Sales$10 million Price / Sales162.16 Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book7.64Miscellaneous Outstanding Shares67,820,000Free Float52,898,000Market Cap$1.62 billion OptionableOptionable Beta-0.88 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.